Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC

Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full ...
Healio

Encorafenib combination secures FDA approval for metastatic colorectal cancer

The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic ...

Pfizer wins full FDA approval for Braftovi in colorectal cancer

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono ...
The Pharma Letter

FDA grants full approval to Pfizer’s Braftovi combo

The US Food and Drug Administration (FDA) has granted full approval to pharma giant Pfizer’s Braftovi (encorafenib) in ...
Contract Pharma

FDA Approves Pfizer’s Braftovi Combination for First-Line Metastatic Colorectal Cancer

The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and ...

FDA watchers warn of 'chaos' inside agency, as regulatory delays, staff hemorrhaging risk America's health

Scientific, political pressures colliding at FDA, delaying rare disease treatment for patients who have few or no options, ...

Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment

Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the ...

Pfizer-backed Priovant wins FDA priority review for lead asset

Pfizer (PFE)-backed Priovant Therapeutics wins U.S. FDA's priority review for skin disorder therapy with a targeted action ...
Fierce Pharma

Pfizer CEO Albert Bourla on FDA official Vinay Prasad: 'We have a problem with the leadership of CBER'

One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...
Benzinga.com

FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuit

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...